LEUKOCARE and Sanofi Pasteur sign cooperation agreement for vaccine stabilization

LEUKOCARE AG, a privately-owned specialist company for protein stabilization and biological surface coating today announced the signing of a cooperation agreement with Sanofi Pasteur, the vaccines division of Sanofi. (EURONEXT: SAN and NYSE: SNY). As part of this cooperation, Sanofi Pasteur will explore LEUKOCARE’s SPS platform technology to enhance the shelf-life of selected vaccine formulations.

LEUKOCARE’s Stabilizing and Protecting Solutions (SPS) are employed in the biopharmaceutical, medical device and diagnostics industries to enhance the shelf-life of proteins and to enable terminal sterilization by irradiation or Ethylene Oxide. Terminal sterilization allows for a significant reduction in production costs by avoiding complex aseptic production and at the same time, improves product safety, as most sources of error can be excluded in one single step.